Literature DB >> 23217427

The enduring legacy of sham-controlled trials of internal mammary artery ligation.

Franklin G Miller1.   

Abstract

In 1959 and 1960 the results of two randomized controlled trials demonstrated that bilateral internal mammary artery ligation was no better than a sham intervention in the treatment of angina. These landmark trials were the first to use blinded placebo controls to evaluate invasive procedures. Revisiting the story of internal mammary artery ligation offers valuable insights into the ethics of sham-controlled trials and the implications of the placebo effect for thinking about risk-benefit assessment of sham procedures. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2012        PMID: 23217427     DOI: 10.1016/j.pcad.2012.09.002

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  5 in total

Review 1.  Systematic review of observational studies reveals no association between low back pain and lumbar spondylolysis with or without isthmic spondylolisthesis.

Authors:  Nicholas S Andrade; Carol M Ashton; Nelda P Wray; Curtis Brown; Viktor Bartanusz
Journal:  Eur Spine J       Date:  2015-04-02       Impact factor: 3.134

2.  Testing for blinding in sham-controlled studies for procedural interventions: the third-party video method.

Authors:  Jennifer Gill; Vinay Prasad
Journal:  CMAJ       Date:  2019-03-11       Impact factor: 8.262

3.  Strengthening the ethical assessment of placebo-controlled surgical trials: three proposals.

Authors:  Wendy Rogers; Katrina Hutchison; Zoë C Skea; Marion K Campbell
Journal:  BMC Med Ethics       Date:  2014-10-23       Impact factor: 2.652

Review 4.  Chronic pancreatitis: review and update of etiology, risk factors, and management.

Authors:  Angela Pham; Christopher Forsmark
Journal:  F1000Res       Date:  2018-05-17

5.  Effect of Permanent Right Internal Mammary Artery Closure on Coronary Collateral Function and Myocardial Ischemia.

Authors:  Michael Stoller; Christian Seiler
Journal:  Circ Cardiovasc Interv       Date:  2017-06       Impact factor: 6.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.